The influence of EDTMP-concentration on the biodistribution of radio- lanthanides and 225-Ac in tumor-bearing mice

Nuclear Medicine and Biology

Volumn 24, Issue 5, 1997, Pages 367-372

  Beyer, G J ^a   Offord, R ^b   Kunzi G ^b   Aleksandrova, Yu ^b   Ravn, U ^b   Jahn, S ^b   Barker, J ^c   Tengblad, O ^c   Lindroos, M ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c CERN   (Switzerland)

Author keywords

Actinium; Biokinetic; EDTMP; Radio lanthanides; Radionuclide therapy

Indexed keywords

ETYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID; LANTHANIDE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DISTRIBUTION; DRUG UPTAKE; GAMMA SPECTROMETRY; ISOTOPE LABELING; MOUSE; NONHUMAN;

EID: 0030850911     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)80001-7     Document Type: Article

References (20)

1. Allen B. J., Blagojevic N. (1996) Alpha and beta emitting radiolanthanides in targeted cancer therapy: The potential role of Terbium-149. Nucl. Med. Com. 17, 40-47.
2. 169Yb binding substances in tumor tissues and liver. Eur. J. Nucl. Med. 7, 298-303.
3. 167Tm-citrate for tumor and liver tissue. Eur. J. Nucl. Med. 8, 440-446.
4. 67Ga-citrate in normal and tumour-bearing mice. Int. J. Appl. Radiat. Isot. 29, 673-680.
5. 167Tm for medical application. In: Radionuclide Imaging 1980 (Vol. 1, p. 587) (IAEA-SM-247/60). IAEA, Vienna.
6. 167Tm-biokinetics in rats. In: ZfK-669, Annual Report 1988 (Edited by Münze R.). Rossendorf, May 1989, p. 98.
7. 225Ac and radio-lanthanides as citrate complexes. Isotapenpraxis 26, 111-114.
8. Beyer G. J., Bergmann R., Kampf G., Mäding, P. and Rösch F. (1992) Simultaneous study of the biodistribution of radio-yttrium complexed with EDTMP and CITRATE ligands in tumour-bearing rats. Int. J. Rad. Appl. Instrum. [B]19, 201.
9. 67Ga in tumor-bearing rats. Eur. J. Nucl. Med. 22(8), 914.
10. Garlich J. R., Simon J. and Masterson T. T. (1990) Method of purifying aminomethylenephosphonic acids for pharmaceutical use. United States Patent 4,937,333, June 26, 1990.
11. 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl. Med. Commun. 14, 121-125.
12. 153Sm chelates: Potential therapeutic bone agents. J. Nucl. Med. 28(4), 495-504.
13. Hisada K., Ando A., Hirakati T. and Ando I. (1971) Recent development of tumor affine radioisotopes. Sogo-Tinsho 20, 1772-1783.
14. Kugler E., Fiander D., Jonson B., Haas H., Przewloka A., Ravn H. L., Simon D. and Zimmer K. (1992) The ISOLDE facility at the CERN PS booster. Nucl. Instr. Meth. B70, 41.
15. Moedritzer K. and Irani R. R. (1966) The direct synthesis of a-amino-methyl-phosphonic acids: Mannich-type reaction with orthophosphorous acid. J. Org. Chem. 34, 1603.
16. 86Y DETMP: Preparation, chemical characterisation and in vivo quantitation of their pharmacological data with PET. Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan, pp. 546-548.
17. Schomäcker K., Franke W. G., Gottschalk A., Hartwig C., Richter A. and Beyer G. J. (1986) Physicochemical properties and biokinetics of tumor-affine metal(M)-ligand complexes. In: Nuclear Medicine in Clinical Oncology (Edited by Winkler C.), pp. 397-401. Springer-Verlag, Berlin, Heidelberg.
18. Schomäcker K., Franke W. G., Beyer G. J. and Münze R. (1986) Radiopharmacology of tumor-seeking trivalent metal complexes. In: Radioaktive Isotope in Klinik und Forschung, Hsg (Edited by Höfer P. and Bergmann H.), pp. 97-102. Verlag H. Egermann, Wien.
19. Schomäcker K., Mocker D., Münze R. and Beyer G. J. (1988) Stability of lanthanide-protein complexes. Int. J. Appl. Radiat. Isot. 39, 261-264.
20. Zak O. and Aisen P. (1988) Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin. Biochemistry 27, 1075-1080.